Alzheimer's Disease Treatments
The UCLA Amyloid Immunotherapy Care Program
The UCLA Amyloid Immunotherapy Care (AIC) Program is at the forefront of Alzheimer’s disease research to target amyloid-beta plaques. The program aims to advance the development of effective immunotherapies that could potentially slow or halt Alzheimer's progression.
Lecanemab
Lecanemab (Leqembi®) is an FDA-approved anti-amyloid monoclonal antibody for early Alzheimer’s disease. It initially received accelerated approval based on the reduction of amyloid beta plaques, and in July 2023, the FDA converted it to full traditional approval after a confirmatory Phase 3 trial demonstrated clinical benefit. Lecanemab is administered as an intravenous infusion every two weeks during the initiation phase.
Donanemab
Donanemab (Kisunla®) is an FDA-approved, once-monthly IV anti-amyloid therapy for early symptomatic Alzheimer’s disease in individuals with confirmed amyloid pathology. It received traditional FDA approval in July 2024. Clinical trials showed it slows cognitive and functional decline and reduces amyloid plaque burden.